Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.
复制标题
DOI:
10.1016/j.ccr.2013.12.015
复制
发表时间:
2014-01-13
期刊:
影响因子:
50.3
通讯作者:
Golub TR
中科院分区:
文献类型:
--
作者:
Lohr JG;Stojanov P;Carter SL;Cruz-Gordillo P;Lawrence MS;Auclair D;Sougnez C;Knoechel B;Gould J;Saksena G;Cibulskis K;McKenna A;Chapman MA;Straussman R;Levy J;Perkins LM;Keats JJ;Schumacher SE;Rosenberg M;Multiple Myeloma Research Consortium;Getz G;Golub TR
We performed massively parallel sequencing of paired tumor/normal samples from 203 multiple myeloma (MM) patients and identified significantly mutated genes and copy number alterations, and discovered putative tumor suppressor genes by determining homozygous deletions and loss-of-heterozygosity. We observed frequent mutations in KRAS (particularly in previously treated patients), NRAS, BRAF, FAM46C, TP53 and DIS3 (particularly in non-hyperdiploid MM). Mutations were often present in subclonal populations, and multiple mutations within the same pathway (e.g. KRAS, NRAS and BRAF) were observed in the same patient. In vitro modeling predicts only partial treatment efficacy of targeting subclonal mutations, and even growth promotion of non-mutated subclones in some cases. These results emphasize the importance of heterogeneity analysis for treatment decisions.
登录
查看更多内容
影响因子:
20.3
作者:
Chen, Lijuan;Wang, Siqing;Zhan, Fenghuang
通讯作者:
Zhan, Fenghuang
影响因子:
64.8
作者:
通讯作者:
--
影响因子:
20.3
作者:
Annunziata, Christina M.;Hernandez, Lidia;Staudt, Louis M.
通讯作者:
Staudt, Louis M.
DOI:
10.1073/pnas.0710052104
发表时间:
2007-12-11
影响因子:
11.1
作者:
Beroukhim, Rameen;Getz, Gad;Sellers, William R.
通讯作者:
Sellers, William R.
影响因子:
12.3
作者:
Fisher S;Barry A;Abreu J;Minie B;Nolan J;Delorey TM;Young G;Fennell TJ;Allen A;Ambrogio L;Berlin AM;Blumenstiel B;Cibulskis K;Friedrich D;Johnson R;Juhn F;Reilly B;Shammas R;Stalker J;Sykes SM;Thompson J;Walsh J;Zimmer A;Zwirko Z;Gabriel S;Nicol R;Nusbaum C
通讯作者:
Nusbaum C